DE60121986T2 - Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen - Google Patents

Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen Download PDF

Info

Publication number
DE60121986T2
DE60121986T2 DE60121986T DE60121986T DE60121986T2 DE 60121986 T2 DE60121986 T2 DE 60121986T2 DE 60121986 T DE60121986 T DE 60121986T DE 60121986 T DE60121986 T DE 60121986T DE 60121986 T2 DE60121986 T2 DE 60121986T2
Authority
DE
Germany
Prior art keywords
hydrochloride
compound
nmr
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60121986T
Other languages
German (de)
English (en)
Other versions
DE60121986D1 (de
Inventor
Hariharan San Diego VENKATESAN
P. James Atlanta SNYDER
C. Dennis Atlanta LIOTTA
Susheng Clarkston WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of DE60121986D1 publication Critical patent/DE60121986D1/de
Application granted granted Critical
Publication of DE60121986T2 publication Critical patent/DE60121986T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/04Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/001Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
    • C07C37/002Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by transformation of a functional group, e.g. oxo, carboxyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/14Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE60121986T 2000-10-02 2001-10-02 Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen Expired - Lifetime DE60121986T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23755700P 2000-10-02 2000-10-02
US237557P 2000-10-02
PCT/US2001/030951 WO2002028862A2 (en) 2000-10-02 2001-10-02 Triptolide analogs for the treatment of autoimmune and inflammatory disorders

Publications (2)

Publication Number Publication Date
DE60121986D1 DE60121986D1 (de) 2006-09-14
DE60121986T2 true DE60121986T2 (de) 2007-07-26

Family

ID=22894243

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60121986T Expired - Lifetime DE60121986T2 (de) 2000-10-02 2001-10-02 Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
DE60142313T Expired - Lifetime DE60142313D1 (de) 2000-10-02 2001-10-02 Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60142313T Expired - Lifetime DE60142313D1 (de) 2000-10-02 2001-10-02 Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen

Country Status (8)

Country Link
US (3) US6777441B2 (https=)
EP (2) EP1330459B1 (https=)
JP (2) JP4269144B2 (https=)
AT (2) ATE469907T1 (https=)
AU (2) AU9654201A (https=)
CA (1) CA2424555A1 (https=)
DE (2) DE60121986T2 (https=)
WO (1) WO2002028862A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028862A2 (en) 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2468277A1 (en) * 2002-05-31 2012-06-27 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
WO2004023984A2 (en) * 2002-09-13 2004-03-25 Smith C Steven Novel composition and method for treatment of upper respiratory conditions
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2005012294A1 (en) * 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
WO2005062913A2 (en) * 2003-12-24 2005-07-14 Pharmagenesis, Inc. Triplide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (en) * 2004-02-09 2009-09-16 Pharmagenesis Inc METHOD OF ISOLATING TRIPTOLIDE COMPOUNDS FROM TRIPTERYGIUM WILFORDII
WO2005084365A2 (en) * 2004-03-02 2005-09-15 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006012204A2 (en) * 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
WO2006044496A2 (en) * 2004-10-13 2006-04-27 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
WO2007053844A2 (en) * 2005-10-31 2007-05-10 Rigel Pharmaceuticals, Inc. Compositions and methods for treating inflammatory disorders
EP2240460A4 (en) * 2008-01-07 2012-02-22 Univ Emory BRANCHED DIEPXYDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
US8147882B2 (en) 2009-09-30 2012-04-03 Leonard Lomax Herbal pain killer compositions
CN104478832B (zh) * 2015-01-05 2016-04-20 项敬来 二萜化合物,含其的药物组合物及其制备方法和应用
JP6743135B2 (ja) * 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1179866A (en) * 1967-09-08 1970-02-04 Agfa Gevaert Nv Photopolymerisation of Ethylenically Unsaturated Organic Compounds
US3917652A (en) * 1968-04-29 1975-11-04 Hoffmann La Roche Juvabione and derivatives thereof
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816437A (en) * 1972-12-22 1974-06-11 Sandoz Ag Thieno(2,3-g)indazoles
US3957816A (en) * 1973-01-31 1976-05-18 Sandoz, Inc. Substituted naphtho pyrazoles
JPS5473766A (en) 1977-11-21 1979-06-13 Nippon Terpen Kagaku Kk Manufacture of menthofuran
GB2104516B (en) 1981-07-13 1985-12-04 Univ Brunel M-alkylphenol derivatives and their use in copper extraction
DE3219048A1 (de) 1982-05-21 1983-11-24 Basf Ag, 6700 Ludwigshafen Thermoplastische formmassen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3440826A1 (de) 1983-11-10 1985-05-23 Basf Ag, 6700 Ludwigshafen 1,1-ethanoretinsaeuren und ihre c(pfeil abwaerts)1(pfeil abwaerts)-c(pfeil abwaerts)4(pfeil abwaerts)-alkylester
JPS61197573A (ja) 1985-02-26 1986-09-01 Chugai Pharmaceut Co Ltd 5,6−エポキシ化トランスビタミンd3
JP2865211B2 (ja) 1988-09-15 1999-03-08 ファルマシア・アンド・アップジョン・カンパニー 5’―インドリニル―5β―アミドメチルオキサゾリジン―2―オン類、3―(縮合環置換)フェニル―5β―アミドメチルオキサゾリジン―2―オン類および3―(窒素原子置換)フェニル―5β―アミドメチルオキサゾリジン―2―オン類
DE3913310A1 (de) 1989-04-20 1990-10-25 Schering Ag Spirocyclopropane in der vitamin d-reihe
JPH03197464A (ja) 1989-12-16 1991-08-28 Basf Ag 置換アゾリルメチルシクロアルカノール及びこれを含有する殺菌剤
US5430054A (en) * 1989-12-22 1995-07-04 Jiangsu Family Planning Institute Preparation methods of diterpene lactone compounds and application of the same to antifertility
AU7570191A (en) * 1990-03-14 1991-10-10 Board Of Regents, The University Of Texas System Tripterygium wilfordii hook f extracts and components thereof for immunosuppression
US5216175A (en) * 1990-03-23 1993-06-01 Sri International Antimalarial analogs of artemisinin
US5581004A (en) * 1991-09-23 1996-12-03 Board Of Regents Of The University Of Nebraska Preparation and use of (2-butene-1,4-diyl) magnesium complexes in organic synthesis
AU2466092A (en) 1992-07-22 1994-02-14 Michael F. Lucey Highly filled polymeric compositions
WO1994026265A1 (en) * 1993-05-06 1994-11-24 Pharmagenesis, Inc. 16-hydroxytriptolide composition and method for immunotherapy
FR2707992B1 (fr) 1993-07-21 1995-10-13 Flamel Tech Sa Nouveaux produits organiques contenant des fonctions thiols réactives, l'un de leurs procédés de préparation et les biomatériaux les contenant.
GB9325415D0 (en) 1993-12-13 1994-02-16 Res Inst Medicine Chem Chemical compounds
GB9405715D0 (en) 1994-03-23 1994-05-11 Res Inst Medicine Chem Chemical compounds
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5723632A (en) * 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
IT1287174B1 (it) 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
US5972998A (en) * 1997-05-23 1999-10-26 Hoechst Marion Roussel, Inc. Triptolide derivatives useful in the treatment of autoimmune diseases
WO1999019298A1 (en) 1997-10-14 1999-04-22 The Scripps Research Institute iso-CBI AND iso-CI ANALOGS OF CC-1065 AND THE DUOCARMYCINS
NZ504884A (en) 1997-12-08 2002-10-25 Scripps Research Inst Synthesis of the dihydroindole C-ring of CC-1065/duocarmycin analogs and certain intermediates
DE19855859A1 (de) * 1998-12-03 2000-06-08 Degussa Katalysatoren für die enantioselektive Epoxidierung von C=C-Doppelbindungen
FR2787451B1 (fr) * 1998-12-18 2001-01-26 Adir Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AR023071A1 (es) 1998-12-23 2002-09-04 Syngenta Participations Ag Compuestos de piridincetona, compuestos intermediarios, composicion herbicida e inhibidora del crecimiento de plantas, metodo para controlar la vegetacion indeseada, metodo para inhibir el crecimiento de las plantas, y uso de la composicion para controlar el crecimiento indeseado de plantas.
US6331642B1 (en) 1999-07-12 2001-12-18 Hoffmann-La Roche Inc. Vitamin D3 analogs
WO2002028862A2 (en) * 2000-10-02 2002-04-11 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
US20040204394A1 (en) * 2003-04-11 2004-10-14 Aderis Pharmaceuticals, Inc. Triptolide analogues

Also Published As

Publication number Publication date
AU9654201A (en) 2002-04-15
WO2002028862A2 (en) 2002-04-11
US8193249B2 (en) 2012-06-05
WO2002028862A3 (en) 2002-09-12
ATE334986T1 (de) 2006-08-15
DE60121986D1 (de) 2006-09-14
JP2004525082A (ja) 2004-08-19
DE60142313D1 (de) 2010-07-15
US20060040907A1 (en) 2006-02-23
EP1659125A1 (en) 2006-05-24
AU2001296542B9 (en) 2002-04-15
CA2424555A1 (en) 2002-04-11
US7557139B2 (en) 2009-07-07
JP4269144B2 (ja) 2009-05-27
AU2001296542B2 (en) 2007-10-25
JP2009102371A (ja) 2009-05-14
US20030027806A1 (en) 2003-02-06
US20090234000A1 (en) 2009-09-17
EP1659125B1 (en) 2010-06-02
US6777441B2 (en) 2004-08-17
EP1330459B1 (en) 2006-08-02
ATE469907T1 (de) 2010-06-15
EP1330459A2 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
DE60121986T2 (de) Triptpolidanaloge zur verendung in der behandlung von autoimmunbedingten und entzündlichen erkrankungen
DE69331954T2 (de) Squalen-synthase-inhibitoren mit cycloalkylamin-bis-aryl-struktur
CH616669A5 (https=)
JP2004525082A5 (https=)
AU2001296542A1 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
EP0025192B1 (de) Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel
DE2525512C2 (https=)
EP1032572B1 (de) Pyranone, verfahren zu ihrer herstellung und verwendung
EP1124809B1 (de) Benzoylpyridazine
DE69232046T2 (de) 2,4-diaryl-1,3-dithiolane als platelet activating faktor rezeptorblocker und 5-lipoxygenasehemmer
EP0046961B1 (de) Epoxi-cycloalkylalkancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel
DE10244810A1 (de) Neue Morpholin-überbrückte Indazolderivate
DE60131416T2 (de) Chirale fluochinolon-argininsalzformen
EP0259782A1 (de) Neue Naphtalin- und Indanderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu deren Herstellung
CH626085A5 (https=)
DE3041097A1 (de) Substituierte oxocarbonsaeuren, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
DE69108564T2 (de) Entzündungshemmende verbindungen.
DE3146867C2 (https=)
EP0000693A1 (de) Aminophenoxymethyl-2-morpholinderivate, ihre Herstellung und sie enthaltende Arzneimittel
WO2002034715A1 (de) Benzamidin-derivate mit einer sulfat-gruppe als ltb4-antagonisten
DE2814168A1 (de) Neue 1- eckige klammer auf 3-(3,4,5- trimethoxyphenoxy)-2-hydroxypropyl eckige klammer zu -4-aryl-piperazin-derivate und verfahren zu ihrer herstellung
EP0281121A1 (de) 1-(1-Aryl-2-hydroxy-ethyl)-imidazole und deren Salze, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP0764637A2 (de) 2-Cyano-3-mercaptocrotonsäureamide
AU2007237317A1 (en) Triptolide analogs for the treatment of autoimmune and inflammatory disorders
WO2002034761A1 (de) Pyranosidderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition